RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in vitro diagnostic company committed to transforming the management of heart disease, today announced at the Annual Meeting of the American Association for Clinical Chemistry at the Los Angeles Convention Center in Los Angeles, the presentation of key findings supporting the benefits of high-throughput nuclear magnetic resonance (NMR) spectroscopy analysis as a powerful analytical tool for medical diagnosis related to atherosclerosis, diabetes and oncology. Three scientific posters will be presented today during the conference that focus on this technology.
Large clinical studies have demonstrated that measurement of LDL particle count (LDL-P) using NMR spectroscopy is a more accurate predictor of cardiovascular events than LDL-C. Until now, NMR technology has been provided as a laboratory-developed test performed at LipoScience, a central laboratory, using the current NMR Profiler® system. As indicated in the posters to be presented, LipoScience is developing the first fully automated NMR clinical diagnostic platform, the Vantera® Clinical Analyzer, which will enable any laboratory to perform the NMR LipoProfile test, pending clearance by the U.S. Food and Drug Administration (FDA). This should ultimately lead to the decentralization of access to LipoScience’s technology.
Study results indicate the Vantera performance characteristics are equivalent to that of the current NMR Profiler. The new Vantera analyzer is a fully automated platform that enables routine high-throughput NMR analysis of bio-fluids for medical diagnostics, which LipoScience believes has widespread potential in areas including atherosclerosis, diabetes and oncology. LipoScience submitted the Vantera Clinical Analyzer for FDA 510(k) clearance in 2012; the review is ongoing.
“Vantera presents an important step in extending our reach and providing laboratories across the country with the capabilities to effectively utilize NMR technology while maintaining high-throughput and workflow,” said Robert Honigberg, M.D., Chief Medical Officer and Vice President, Medical Affairs of LipoScience. “The studies presented at AACC highlight the potential of Vantera as a tool in helping patient populations recognize and manage cardiovascular risk through knowledge of LDL and HDL particle count.”
LipoScience AACC Poster Presentation Details: Tuesday, July 17
-
Performance Evaluation of the Measurement of LDL particle number on
the Vantera® Clinical Analyzer
Lead presenter: Paul Braun
Time: 10:00 a.m.-12:30 p.m.
Session A
-
Performance Characteristics for HDL particle measurement using the
Vantera® Clinical Analyzer
Lead presenter: Steve Maytus
Time: 10:00 a.m.-12:30 p.m.
Session A
-
Introduction of the Vantera® Clinical Analyzer for NMR-Based Testing
Lead presenter: Elias Jeyarajah
Time: 2:00 p.m.-4:30 p.m.
Session B
For more information on LipoScience or the Vantera Clinical Analyzer, please visit http://www.liposcience.com or visit the LipoScience, Inc. booth at # 4524.
About LipoScience, Inc.
LipoScience, Inc. is an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary technology platform based on nuclear magnetic resonance (NMR) technology. Our first diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 7 million NMR LipoProfile tests have been ordered by clinicians. For further information on the Company, please visit www.liposcience.com and www.theparticletest.com.